ADVANCED SOLID TUMOR

This early-phase study tested a combination of two experimental drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors (including melanoma) who had no other good treatment options. The main goal was to check the drug's safety and find the highest safe dose. Researchers also looked at how the drug moves…

This study tested a new drug (TJ004309) alone or with another drug (Toripalimab) in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest and most effective dose, and to see if the combination could shrink tumors…

This early-phase study tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This study tested a new drug called BMS-986315, either alone or combined with other cancer drugs (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right dose. This is an e…

This early-stage trial tested a new drug called PM14 in 126 people with advanced solid tumors that had not responded to standard treatments. The main goals were to find the safest dose and to see if the drug could shrink tumors. The study is now complete, and results will help gu…

This study tested a new drug called JAB-21822 in 29 adults with advanced solid tumors (like lung or colon cancer) that have a specific KRAS G12C mutation. The goal was to see if the drug is safe and can shrink tumors. Participants took the drug by mouth, alone or with another dru…

This early-phase study tested a new drug called HBM1020 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the right dose. The study did not aim to cure the cancer, but to see if the dr…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which blocks blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, kidney, or colorectal cancer. The goal was to find the safest dose and se…

This early-phase study tested a new drug called BR101 in 15 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body an…

This study tested a combination of two drugs, durvalumab (an immunotherapy) and tazemetostat (an epigenetic therapy), in 164 adults with advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The goal was to see if the combo could shrink or stabilize tumors. …

This early-phase study tested a new experimental drug called HMBD-002, alone or with another cancer drug (pembrolizumab), in 48 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see …

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, or head and neck cancer) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. The study is complete, …

This early-stage study tested a new drug called CHS-388 in 145 people with advanced solid tumors (like kidney, liver, or lung cancer) that had stopped responding to standard treatments. The drug works by blocking a protein called IL-27 to help the immune system fight cancer. The …

This study tested a new oral drug called RP-3500 (camonsertib) alone or combined with talazoparib or gemcitabine in 276 adults with advanced solid tumors that have certain gene mutations. The main goals were to find the safest dose and check for side effects. The study also looke…

This early-phase study tested a new antibody (BGB-A445) alone or with another drug (tislelizumab) in 204 people with advanced solid tumors, including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. While the treatment a…

This study tested a drug called PRL3-ZUMAB in 14 adults with advanced solid tumors (including stomach and liver cancers) that had stopped responding to standard therapies. The drug was given intravenously every two weeks. The goal was to see if it could shrink tumors or stop them…

This early-phase trial tested the safety and best dose of combining the diabetes drug pioglitazone with the chemotherapy carboplatin in 14 people with advanced or metastatic solid tumors that could not be cured with standard treatments. The goal was to find the maximum tolerated …

This study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …

This study tested whether combining several immunotherapy drugs could help people with advanced prostate cancer that no longer responds to hormone therapy. 59 adults received one of three drug combinations. The goal was to see if the treatments could shrink tumors or lower PSA le…

This study tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to help the immune system attack cancer cells. The main goal was to see if the drug could shri…

This early-phase study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in 135 people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation). The main goals were to check safety, find the best dose, and see if the drug shrinks t…

This study tested a new drug called LM-108, alone or with an anti-PD-1 antibody, in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Early results focus on controlling tumor growt…

This study tested an experimental drug called LM-302 in 153 adults with advanced solid tumors that have a specific protein (CLDN18.2). The goal was to find a safe dose and see if the drug can shrink tumors. Participants received the drug intravenously, and researchers monitored s…

This early-stage trial tested a therapy made from a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors like melanoma, cervical cancer, and lung cancer. 43 adults participated to find the safest dose and check for side effects. The goal was …

This early-stage study tested a new drug called BAT1308 in 59 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the highest safe dose and check for side effects. Researchers also looked at how the drug moves through th…

This study looked at whether adding a simple blood test (liquid biopsy) to the standard tissue test could help find more gene changes (EGFR mutations) in people with advanced lung cancer. Over 500 patients who had not yet been treated provided both blood and tissue samples. The g…

This study looked at how bosentan, a drug that affects liver enzymes, changes the way the body processes the cancer drug lurbinectedin. It involved 11 adults with advanced solid tumors who had no other treatment options. The goal was to measure drug levels in the blood to underst…